

Missed Ischemia Equals Poorer Care, Survival

BY THERESE DROSTE
Contributing Writer

WASHINGTON — Myocardial infarction patients who lacked documented ischemic symptoms upon hospital admission received lower quality care, were issued fewer established therapies, and had significantly higher risk-adjusted, in-hospital mortality than those with symptoms, Erik Schelbert, M.D., reported at a meeting sponsored by the American Heart Association.

There was significantly less use of aspirin, β -blockers, and reperfusion therapy in those without ischemic symptoms, who were also more likely to be women, nonwhite, and older than the symptomatic patients.

"Curiously, these trends continued until discharge," said Dr. Schelbert of the University of Iowa, Iowa City.

He presented data from the Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery (PREMIER) study, which enrolled 3,960 MI patients in 19 centers during January 2003–June 2004.

'There is evidence of a significant breakdown in communication, and patient symptoms are being missed. The cause of this needs further investigation.'

Dr. Schelbert and his coinvestigators reviewed the charts of 3,825 patients, comparing Centers for Medicare and Medicaid Services performance measures and in-hospital death to determine whether ischemic symptoms were documented. Trauma patients and those with acute GI bleeds, strokes, and hip fractures were excluded.

A subgroup of 2,480 patients was interviewed within 2 days of admission to get their point of view of what brought them to the hospital.

While data from other studies have shown that women, minorities, and older patients often don't show traditional symptoms for MI, this is the first study to include patient interviews in order to link symptoms with outcomes.

Overall, 6.2% of the 3,825 patients had no ischemic symptoms documented in their charts upon admission, but of those who were interviewed, 72% had at least one symptom that would be considered ischemic by current American Heart Association/American College of Cardiology guidelines.

The undocumented symptoms included shortness of breath (50%), chest pain (40%), and nausea (31%).

Although troponin assays confirmed myocardial damage in all patients, the disparities in care persisted through discharge.

"Because the lack of documented symptoms of MI and the following lesser-quality care were linked, we inferred that patients' symptoms were not recognized. Clearly, most patients actually did

have symptoms, as the interviews then showed," said Dr. Schelbert. It's possible that these patients had comorbidities that made a diagnosis of MI more difficult, he added.

Of those asymptomatic patients eligible during hospital admission, 85% received aspirin, compared with 96% of those with symptoms. A total of 64% received β -blockers within 24 hours, compared with 85% of those with symptoms, and 18% received reperfusion therapy, compared with

71% of patients with symptoms, all significant differences.

At discharge, those without ischemic symptoms were less likely than symptomatic patients to receive aspirin (86% vs. 94%), β -blockers (80% vs. 89%), or ACE inhibitors (58% vs. 69%).

Asymptomatic patients also were less likely to receive statin therapy for secondary MI prevention at LDL-cholesterol thresholds of 100 mg/dL (70% vs. 87%) or 70 mg/dL (61% vs. 84%).

The unadjusted in-hospital mortality rates were also higher in those patients who did not have ischemic symptoms (15% vs. 3%).


"There is evidence of a significant breakdown in communication, and patient symptoms are being missed. The cause of this needs further investigation," said Dr. Schelbert.

The study was funded by grants from the Agency for Healthcare Research and Quality and CVT Therapeutics. ■

New Indication in Heart Failure NYHA Class II-IV and LVEF \leq 40%

Add ATACAND today. Because ATACAND can...

Further reduce CV death or HF hospitalization when added to conventional HF therapy including an ACE inhibitor (ACEI)¹



CHARM-Added was a double-blind, placebo-controlled study of 2548 subjects with NYHA Class II-IV HF and LVEF \leq 40% who were randomized to placebo or ATACAND (initially 4-8 mg daily, titrated as tolerated to 32 mg daily) on top of ACE inhibitors and other conventional HF therapies. Median follow-up was 41 months.

ATACAND is indicated for the treatment of heart failure (NYHA Class II-IV) in patients with left-ventricular systolic dysfunction (ejection fraction \leq 40%) to reduce cardiovascular death and to reduce heart failure hospitalizations. (See Clinical Trials.) ATACAND also has an added effect on these outcomes when used with an ACE inhibitor.

The recommended initial dose for treating heart failure is 4 mg once daily. The target dose is 32 mg once daily, which is achieved by doubling the dose at approximately 2-week intervals, as tolerated by the patient.

USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, ATACAND should be discontinued as soon as possible. See WARNINGS, *Fetal/Neonatal Morbidity and Mortality*.

Please see adjacent brief summary of full Prescribing Information, including boxed WARNING regarding use in pregnancy.

Once-A-Day Tablets
Atacand[®]
candesartan cilexetil